BASINGSTOKE, England, November 23 /PRNewswire-FirstCall/ -- The Company announces that it was notified on 22 November 2005 under Sections 198 to 203 of the Companies Act that, at close of business on 17 November 2005, The Goldman Sachs Group, Inc., was interested in 27,000,376 ordinary shares of GBP0.05p each in the capital of the Company. This holding represents 5.452 per cent of the issued ordinary share capital of the Company.
T May Company Secretary Notes to Editors Shire Pharmaceuticals Group plc
Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing and marketing products in the areas of central nervous system (CNS), gastrointestinal (GI), general products and human genetic therapies. Shire has operations in the world’s key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US.
For further information on Shire, please visit the Company’s website: www.shire.com.
Shire Pharmaceuticals Group plc
CONTACT: For further information please contact: Investor Relations: CleaRosenfeld (Rest of the World), +44-(0)1256-894-160 or Brian Piper (NorthAmerica), +1-484-595-8252
